KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $183.0 million.

  • Twist Bioscience's Cash & Equivalents fell 19.12% to $183.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $183.0 million, marking a year-over-year decrease of 19.12%. This contributed to the annual value of $183.0 million for FY2025, which is 19.12% down from last year.
  • According to the latest figures from Q3 2025, Twist Bioscience's Cash & Equivalents is $183.0 million, which was down 9.11% from $201.4 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Cash & Equivalents registered a high of $475.3 million during Q2 2021, and its lowest value of $183.0 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $245.5 million, with a median of $239.1 million in 2024.
  • Over the last 5 years, Twist Bioscience's Cash & Equivalents had its largest YoY gain of 397.32% in 2021, and its largest YoY loss of 45.06% in 2021.
  • Quarterly analysis of 5 years shows Twist Bioscience's Cash & Equivalents stood at $191.6 million in 2021, then surged by 65.26% to $316.7 million in 2022, then dropped by 15.92% to $266.3 million in 2023, then decreased by 16.85% to $221.4 million in 2024, then declined by 19.12% to $183.0 million in 2025.
  • Its Cash & Equivalents was $183.0 million in Q3 2025, compared to $201.4 million in Q2 2025 and $210.4 million in Q1 2025.